Curis LifesciencesNSE:CURIS +0.40%30 ROA % is 11.15% as of Mar. 2026, which is 16% below its 10-year median of 13.23. GuruFocus rates NSE:CURIS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Curis Lifesciences ranks better than 86.14% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Curis Lifesciences's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹69.2 Mil.
Curis Lifesciences's average Total Assets over the quarter that ended in Mar. 2026 was ₹620.3 Mil. Therefore, Curis Lifesciences's annualized ROA % for the quarter that ended in Mar. 2026 was 11.15%.
The historical rank and industry rank for Curis Lifesciences's ROA % or its related term are showing as below:
NSE:CURIS'
s ROA % Range Over the Past 10 Years
Min: 6.3 Med: 13.23 Max: 16.24
Current: 11.15
During the past 4 years, Curis Lifesciences's highest ROA % was 16.24%. The lowest was 6.30%. And the median was 13.23%.
NSE:CURIS's ROA % is ranked better than 86.14% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs NSE:CURIS: 11.15
Curis Lifesciences (NSE:CURIS) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is one times the annual (Mar. 2026) net income data. The Revenue data used here is one times the annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Curis Lifesciences ROA % Related Terms
Curis Lifesciences ROA % Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences ROA % Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
ROA %
6.30
15.30
16.24
11.15
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
ROA %
6.30
15.30
16.24
11.15
NSE:CURIS vs ZTS, UTHR: ROA % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's ROA % distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Curis Lifesciences (NSE:CURIS) has a ROA % of 11.15% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Curis Lifesciences and its competitors. This is 16% below median its historical median of 13.23. Over the past decade, Curis Lifesciences' ROA % has ranged from 6.30 to 16.24. According to the industry distribution chart, Curis Lifesciences ranks #139 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Curis Lifesciences' ROA % too high?
Curis Lifesciences' current ROA % of 11.15% is 16% below median its 10-year median of 13.23. Over the past 10 years, this metric has ranged from a low of 6.30 to a high of 16.24. The Drug Manufacturers industry median ROA % is 2.72. Curis Lifesciences' value of 11.15% is 309.9% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #139 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curis Lifesciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #139 out of 1003 companies for ROA %. This places Curis Lifesciences in the top 14% of its industry — outperforming the majority of peers. The industry median ROA % is 2.72. Curis Lifesciences' value of 11.15% is 309.9% above this benchmark. Historically, Curis Lifesciences' own ROA % has ranged from 6.30 to 16.24 over the past decade. While the company's 10-year median is 13.23 vs. the industry median of 2.72, Curis Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current ROA % of 11.15% is 309.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current ROA % is 11.15%, which is 16% below median its own 10-year median of 13.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current ROA % of 11.15%. The current ROA % is 11.15%, which is 16% below median its 10-year median of 13.23 and 309.9% above the Drug Manufacturers industry median of 2.72. Curis Lifesciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current ROA % is 11.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
30GF Score
Get the complete analysis for NSE:CURIS
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 